Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 81

1.

Favorable incremental cost-effectiveness ratio for lung cancer screening in Italy.

Veronesi G, Navone N, Novellis P, Dieci E, Toschi L, Velutti L, Solinas M, Vanni E, Alloisio M, Ghislandi S.

Lung Cancer. 2020 Mar 19;143:73-79. doi: 10.1016/j.lungcan.2020.03.015. [Epub ahead of print]

PMID:
32234647
2.

First-line pembrolizumab in advanced non-small cell lung cancer patients with poor performance status.

Facchinetti F, Mazzaschi G, Barbieri F, Passiglia F, Mazzoni F, Berardi R, Proto C, Cecere FL, Pilotto S, Scotti V, Rossi S, Del Conte A, Vita E, Bennati C, Ardizzoni A, Cerea G, Migliorino MR, Sala E, Camerini A, Bearz A, De Carlo E, Zanelli F, Guaitoli G, Garassino MC, Ciccone LP, Sartori G, Toschi L, Dall'Olio FG, Landi L, Pizzutilo EG, Bartoli G, Baldessari C, Novello S, Bria E, Cortinovis DL, Rossi G, Rossi A, Banna GL, Camisa R, Di Maio M, Tiseo M.

Eur J Cancer. 2020 Mar 25;130:155-167. doi: 10.1016/j.ejca.2020.02.023. [Epub ahead of print]

PMID:
32220780
3.

Circulating Tumor Cells and Metabolic Parameters in NSCLC Patients Treated with Checkpoint Inhibitors.

Castello A, Carbone FG, Rossi S, Monterisi S, Federico D, Toschi L, Lopci E.

Cancers (Basel). 2020 Feb 19;12(2). pii: E487. doi: 10.3390/cancers12020487.

4.

The use of radiation therapy for oligoprogressive/oligopersistent oncogene-driven non small cell lung cancer: State of the art.

Franceschini D, De Rose F, Cozzi S, Franzese C, Rossi S, Finocchiaro G, Toschi L, Santoro A, Scorsetti M.

Crit Rev Oncol Hematol. 2020 Apr;148:102894. doi: 10.1016/j.critrevonc.2020.102894. Epub 2020 Feb 5. Review.

PMID:
32062314
5.

The immune-metabolic-prognostic index and clinical outcomes in patients with non-small cell lung carcinoma under checkpoint inhibitors.

Castello A, Toschi L, Rossi S, Mazziotti E, Lopci E.

J Cancer Res Clin Oncol. 2020 Feb 11. doi: 10.1007/s00432-020-03150-9. [Epub ahead of print]

PMID:
32048008
6.

Preliminary data on circulating tumor cells in metastatic NSCLC patients candidate to immunotherapy.

Monterisi S, Castello A, Toschi L, Federico D, Rossi S, Veronesi G, Lopci E.

Am J Nucl Med Mol Imaging. 2019 Dec 15;9(6):282-295. eCollection 2019.

7.

Hyper-progressive Disease in Patients With Non-Small Cell Lung Cancer Treated With Checkpoint Inhibitors: The Role of 18F-FDG PET/CT.

Castello A, Rossi S, Toschi L, Mazziotti E, Lopci E.

J Nucl Med. 2019 Dec 20. pii: jnumed.119.237768. doi: 10.2967/jnumed.119.237768. [Epub ahead of print]

PMID:
31862803
8.

Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer.

Landi L, D'Incà F, Gelibter A, Chiari R, Grossi F, Delmonte A, Passaro A, Signorelli D, Gelsomino F, Galetta D, Giannarelli D, Soto Parra H, Minuti G, Tiseo M, Migliorino MR, Cognetti F, Toschi L, Bidoli P, Piantedosi F, Calabro' L, Cappuzzo F.

J Immunother Cancer. 2019 Nov 21;7(1):316. doi: 10.1186/s40425-019-0793-8.

9.

Survival outcome of tyrosine kinase inhibitors beyond progression in association to radiotherapy in oligoprogressive EGFR-mutant non-small-cell lung cancer.

Rossi S, Finocchiaro G, Noia VD, Bonomi M, Cerchiaro E, Rose F, Franceschini D, Navarria P, Ceresoli GL, Beretta GD, D'Argento E, Scorsetti M, Santoro A, Toschi L.

Future Oncol. 2019 Nov;15(33):3775-3782. doi: 10.2217/fon-2019-0349. Epub 2019 Nov 11.

PMID:
31709807
10.

Real-life results from the overall population and key subgroups within the Italian cohort of nivolumab expanded access program in non-squamous non-small cell lung cancer.

Grossi F, Genova C, Crinò L, Delmonte A, Turci D, Signorelli D, Passaro A, Soto Parra H, Catino A, Landi L, Gelsomino F, Tiseo M, Puppo G, Roila F, Ricciardi S, Tonini G, Cognetti F, Toschi L, Tassinari D, Scoppola A, Giannarelli D, Cortesi E.

Eur J Cancer. 2019 Dec;123:72-80. doi: 10.1016/j.ejca.2019.09.011. Epub 2019 Oct 28.

PMID:
31671314
11.

Independent expression of circulating and tissue levels of PD-L1: correlation of clusters with tumor metabolism and outcome in patients with non-small cell lung cancer.

Grizzi F, Castello A, Qehajaj D, Toschi L, Rossi S, Pistillo D, Paleari V, Veronesi G, Novellis P, Monterisi S, Mineri R, Rahal D, Lopci E.

Cancer Immunol Immunother. 2019 Sep;68(9):1537-1545. doi: 10.1007/s00262-019-02387-9. Epub 2019 Sep 3.

PMID:
31482306
12.

Predictive and Prognostic Role of Metabolic Response in Patients With Stage III NSCLC Treated With Neoadjuvant Chemotherapy.

Castello A, Toschi L, Rossi S, Finocchiaro G, Grizzi F, Mazziotti E, Qehajaj D, Rahal D, Lopci E.

Clin Lung Cancer. 2020 Jan;21(1):28-36. doi: 10.1016/j.cllc.2019.07.004. Epub 2019 Jul 22.

PMID:
31409523
13.

Nivolumab in disadvantaged subgroups of metastatic non-small-cell lung cancer patients: a single-institution experience.

Rossi S, Finocchiaro G, Toschi L, Santoro A.

Immunotherapy. 2019 Aug;11(11):945-952. doi: 10.2217/imt-2019-0029. Epub 2019 Jun 14.

PMID:
31199183
14.

Peritoneal carcinomatosis in non-small-cell lung cancer: retrospective multicentric analysis and literature review.

Abbate MI, Cortinovis DL, Tiseo M, Vavalà T, Cerea G, Toschi L, Canova S, Colonese F, Bidoli P.

Future Oncol. 2019 Mar;15(9):989-994. doi: 10.2217/fon-2018-0469. Epub 2019 Jan 25. Review.

PMID:
30681378
15.

Activity of EGFR TKIs in Caucasian Patients With NSCLC Harboring Potentially Sensitive Uncommon EGFR Mutations.

Passaro A, Prelaj A, Bonanno L, Tiseo M, Tuzi A, Proto C, Chiari R, Rocco D, Genova C, Sini C, Cortinovis D, Pilotto S, Landi L, Bennati C, Camerini A, Toschi L, Putzu C, Cerea G, Spitaleri G, Cappuzzo F, de Marinis F.

Clin Lung Cancer. 2019 Mar;20(2):e186-e194. doi: 10.1016/j.cllc.2018.11.005. Epub 2018 Nov 20.

PMID:
30563752
16.

Spindle Cell Nuclear in Testis Carcinoma of the Lung: A Challenging Tumor.

Pelosi G, Cannone M, Balladore E, Rahal D, Bossi P, Novellis P, Bottoni E, Toschi L, Roncalli M, French CA, Veronesi G.

J Thorac Oncol. 2019 Feb;14(2):311-313. doi: 10.1016/j.jtho.2018.11.010. Epub 2018 Nov 23. No abstract available.

17.

Impact of Exon 19 Deletion Subtypes in EGFR-Mutant Metastatic Non-Small-Cell Lung Cancer Treated With First-Line Tyrosine Kinase Inhibitors.

Rossi S, Toschi L, Finocchiaro G, Di Noia V, Bonomi M, Cerchiaro E, Ceresoli GL, Beretta GD, D'Argento E, Santoro A.

Clin Lung Cancer. 2019 Mar;20(2):82-87. doi: 10.1016/j.cllc.2018.10.009. Epub 2018 Nov 2.

PMID:
30473385
18.

Preclinical Efficacy of the Novel Monocarboxylate Transporter 1 Inhibitor BAY-8002 and Associated Markers of Resistance.

Quanz M, Bender E, Kopitz C, Grünewald S, Schlicker A, Schwede W, Eheim A, Toschi L, Neuhaus R, Richter C, Toedling J, Merz C, Lesche R, Kamburov A, Siebeneicher H, Bauser M, Hägebarth A.

Mol Cancer Ther. 2018 Nov;17(11):2285-2296. doi: 10.1158/1535-7163.MCT-17-1253. Epub 2018 Aug 16.

19.

Immunotherapy in non-small-cell lung cancer: potential predictors of response and new strategies to assess activity.

Rossi S, Castello A, Toschi L, Lopci E.

Immunotherapy. 2018 Jul;10(9):797-805. doi: 10.2217/imt-2017-0187. Review.

PMID:
30008262
20.

Tumor heterogeneity, hypoxia, and immune markers in surgically resected non-small-cell lung cancer.

Castello A, Grizzi F, Toschi L, Rossi S, Rahal D, Marchesi F, Russo C, Finocchiaro G, Lopci E.

Nucl Med Commun. 2018 Jul;39(7):636-644. doi: 10.1097/MNM.0000000000000832.

PMID:
29608508
21.

Checkpoint inhibitors: 'raising the bar' also in brain metastases from non-small-cell lung cancer?

Rossi S, Finocchiaro G, Marchetti S, Toschi L, Santoro A.

Immunotherapy. 2018 Apr;10(5):403-410. doi: 10.2217/imt-2017-0151. Review.

PMID:
29473467
22.

Non-small cell lung cancer treatment (r)evolution: ten years of advances and more to come.

Toschi L, Rossi S, Finocchiaro G, Santoro A.

Ecancermedicalscience. 2017 Nov 30;11:787. doi: 10.3332/ecancer.2017.787. eCollection 2017. Review.

23.

Clinical characteristics of patient selection and imaging predictors of outcome in solid tumors treated with checkpoint-inhibitors.

Rossi S, Toschi L, Castello A, Grizzi F, Mansi L, Lopci E.

Eur J Nucl Med Mol Imaging. 2017 Dec;44(13):2310-2325. doi: 10.1007/s00259-017-3802-5. Epub 2017 Aug 16. Review.

PMID:
28815334
24.

Early and delayed evaluation of solid tumours with 64Cu-ATSM PET/CT: a pilot study on semiquantitative and computer-aided fractal geometry analysis.

Lopci E, Grizzi F, Russo C, Toschi L, Grassi I, Cicoria G, Lodi F, Mattioli S, Fanti S.

Nucl Med Commun. 2017 Apr;38(4):340-346. doi: 10.1097/MNM.0000000000000656.

PMID:
28263239
25.

Outcome appraisal of patients with limited brain metastases (BMs) from non small cell lung cancer (NSCLC) treated with different local therapeutic strategies: a single institute evaluation.

Pessina F, Navarria P, Cozzi L, Tomatis S, Ascolese AM, Franzese C, Toschi L, Santoro A, De Rose F, Franceschini D, Bello L, Scorsetti M.

Br J Radiol. 2017 Apr;90(1072):20170022. doi: 10.1259/bjr.20170022. Epub 2017 Mar 3.

26.

Pan-mutant-IDH1 inhibitor BAY1436032 is highly effective against human IDH1 mutant acute myeloid leukemia in vivo.

Chaturvedi A, Herbst L, Pusch S, Klett L, Goparaju R, Stichel D, Kaulfuss S, Panknin O, Zimmermann K, Toschi L, Neuhaus R, Haegebarth A, Rehwinkel H, Hess-Stumpp H, Bauser M, Bochtler T, Struys EA, Sharma A, Bakkali A, Geffers R, Araujo-Cruz MM, Thol F, Gabdoulline R, Ganser A, Ho AD, von Deimling A, Rippe K, Heuser M, Krämer A.

Leukemia. 2017 Oct;31(10):2020-2028. doi: 10.1038/leu.2017.46. Epub 2017 Jan 31.

27.

Pan-mutant IDH1 inhibitor BAY 1436032 for effective treatment of IDH1 mutant astrocytoma in vivo.

Pusch S, Krausert S, Fischer V, Balss J, Ott M, Schrimpf D, Capper D, Sahm F, Eisel J, Beck AC, Jugold M, Eichwald V, Kaulfuss S, Panknin O, Rehwinkel H, Zimmermann K, Hillig RC, Guenther J, Toschi L, Neuhaus R, Haegebart A, Hess-Stumpp H, Bauser M, Wick W, Unterberg A, Herold-Mende C, Platten M, von Deimling A.

Acta Neuropathol. 2017 Apr;133(4):629-644. doi: 10.1007/s00401-017-1677-y. Epub 2017 Jan 25.

PMID:
28124097
28.

Correlation of metabolic information on FDG-PET with tissue expression of immune markers in patients with non-small cell lung cancer (NSCLC) who are candidates for upfront surgery.

Lopci E, Toschi L, Grizzi F, Rahal D, Olivari L, Castino GF, Marchetti S, Cortese N, Qehajaj D, Pistillo D, Alloisio M, Roncalli M, Allavena P, Santoro A, Marchesi F, Chiti A.

Eur J Nucl Med Mol Imaging. 2016 Oct;43(11):1954-61. doi: 10.1007/s00259-016-3425-2. Epub 2016 Jun 1.

PMID:
27251642
29.

Survival outcomes and incidence of brain recurrence in high-grade neuroendocrine carcinomas of the lung: Implications for clinical practice.

Metro G, Ricciuti B, Chiari R, Baretti M, Falcinelli L, Giannarelli D, Sidoni A, Mountzios G, Crinò L, Bellezza G, Rebonato A, Ferolla P, Toschi L.

Lung Cancer. 2016 May;95:82-7. doi: 10.1016/j.lungcan.2016.03.006. Epub 2016 Mar 15.

PMID:
27040856
30.

Effect of oncogene activating mutations and kinase inhibitors on amino acid metabolism of human isogenic breast cancer cells.

Kim ES, Samanta A, Cheng HS, Ding Z, Han W, Toschi L, Chang YT.

Mol Biosyst. 2015 Dec;11(12):3378-86. doi: 10.1039/c5mb00525f.

PMID:
26469267
31.

Clinical Outcome of Stereotactic Ablative Body Radiotherapy for Lung Metastatic Lesions in Non-small Cell Lung Cancer Oligometastatic Patients.

De Rose F, Cozzi L, Navarria P, Ascolese AM, Clerici E, Infante M, Alloisio M, Testori A, Toschi L, Finocchiaro G, Santoro A, Scorsetti M.

Clin Oncol (R Coll Radiol). 2016 Jan;28(1):13-20. doi: 10.1016/j.clon.2015.08.011. Epub 2015 Sep 15.

PMID:
26385822
32.

Prognostic and predictive value of MET deregulation in non-small cell lung cancer.

Finocchiaro G, Toschi L, Gianoncelli L, Baretti M, Santoro A.

Ann Transl Med. 2015 Apr;3(6):83. doi: 10.3978/j.issn.2305-5839.2015.03.43. Review.

33.

Long-Term Follow-up Results of the DANTE Trial, a Randomized Study of Lung Cancer Screening with Spiral Computed Tomography.

Infante M, Cavuto S, Lutman FR, Passera E, Chiarenza M, Chiesa G, Brambilla G, Angeli E, Aranzulla G, Chiti A, Scorsetti M, Navarria P, Cavina R, Ciccarelli M, Roncalli M, Destro A, Bottoni E, Voulaz E, Errico V, Ferraroli G, Finocchiaro G, Toschi L, Santoro A, Alloisio M; DANTE Study Group.

Am J Respir Crit Care Med. 2015 May 15;191(10):1166-75. doi: 10.1164/rccm.201408-1475OC.

PMID:
25760561
34.

PET radiopharmaceuticals for imaging of tumor hypoxia: a review of the evidence.

Lopci E, Grassi I, Chiti A, Nanni C, Cicoria G, Toschi L, Fonti C, Lodi F, Mattioli S, Fanti S.

Am J Nucl Med Mol Imaging. 2014 Jun 7;4(4):365-84. eCollection 2014. Review.

35.

Increased SOX2 gene copy number is associated with FGFR1 and PIK3CA gene gain in non-small cell lung cancer and predicts improved survival in early stage disease.

Toschi L, Finocchiaro G, Nguyen TT, Skokan MC, Giordano L, Gianoncelli L, Perrino M, Siracusano L, Di Tommaso L, Infante M, Alloisio M, Roncalli M, Scorsetti M, Jänne PA, Santoro A, Varella-Garcia M.

PLoS One. 2014 Apr 15;9(4):e95303. doi: 10.1371/journal.pone.0095303. eCollection 2014.

36.

Isogenic human mammary epithelial cell lines: novel tools for target identification and validation. Comprehensive characterization of an isogenic human mammary epithelial cell model provides evidence for epithelial-mesenchymal transition.

Ulbricht U, Sommer A, Beckmann G, Lutzenberger M, Seidel H, Kreft B, Toschi L.

Breast Cancer Res Treat. 2013 Apr;138(2):437-56. doi: 10.1007/s10549-013-2472-7. Epub 2013 Mar 13.

PMID:
23483306
37.

Specific PET imaging of xC- transporter activity using a ¹⁸F-labeled glutamate derivative reveals a dominant pathway in tumor metabolism.

Koglin N, Mueller A, Berndt M, Schmitt-Willich H, Toschi L, Stephens AW, Gekeler V, Friebe M, Dinkelborg LM.

Clin Cancer Res. 2011 Sep 15;17(18):6000-11. doi: 10.1158/1078-0432.CCR-11-0687. Epub 2011 Jul 12.

38.

Predictive biomarker discovery through the parallel integration of clinical trial and functional genomics datasets.

Swanton C, Larkin JM, Gerlinger M, Eklund AC, Howell M, Stamp G, Downward J, Gore M, Futreal PA, Escudier B, Andre F, Albiges L, Beuselinck B, Oudard S, Hoffmann J, Gyorffy B, Torrance CJ, Boehme KA, Volkmer H, Toschi L, Nicke B, Beck M, Szallasi Z.

Genome Med. 2010 Aug 11;2(8):53. doi: 10.1186/gm174.

39.

Impact of biomarkers on non-small cell lung cancer treatment.

Toschi L, Cappuzzo F.

Target Oncol. 2010 Mar;5(1):5-17. doi: 10.1007/s11523-010-0132-y. Epub 2010 May 5. Review.

PMID:
20443070
40.

Clinical implications of MET gene copy number in lung cancer.

Toschi L, Cappuzzo F.

Future Oncol. 2010 Feb;6(2):239-47. doi: 10.2217/fon.09.164. Review.

PMID:
20146583
41.

Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC.

Turke AB, Zejnullahu K, Wu YL, Song Y, Dias-Santagata D, Lifshits E, Toschi L, Rogers A, Mok T, Sequist L, Lindeman NI, Murphy C, Akhavanfard S, Yeap BY, Xiao Y, Capelletti M, Iafrate AJ, Lee C, Christensen JG, Engelman JA, Jänne PA.

Cancer Cell. 2010 Jan 19;17(1):77-88. doi: 10.1016/j.ccr.2009.11.022.

42.

Insulin-like growth factor receptor 1 (IGF1R) expression and survival in surgically resected non-small-cell lung cancer (NSCLC) patients.

Cappuzzo F, Tallini G, Finocchiaro G, Wilson RS, Ligorio C, Giordano L, Toschi L, Incarbone M, Cavina R, Terracciano L, Roncalli M, Alloisio M, Varella-Garcia M, Franklin WA, Santoro A.

Ann Oncol. 2010 Mar;21(3):562-7. doi: 10.1093/annonc/mdp357. Epub 2009 Sep 18.

43.

Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients.

Cappuzzo F, Marchetti A, Skokan M, Rossi E, Gajapathy S, Felicioni L, Del Grammastro M, Sciarrotta MG, Buttitta F, Incarbone M, Toschi L, Finocchiaro G, Destro A, Terracciano L, Roncalli M, Alloisio M, Santoro A, Varella-Garcia M.

J Clin Oncol. 2009 Apr 1;27(10):1667-74. doi: 10.1200/JCO.2008.19.1635. Epub 2009 Mar 2.

44.

Gemcitabine for the treatment of advanced nonsmall cell lung cancer.

Toschi L, Cappuzzo F.

Onco Targets Ther. 2009 Feb 18;2:209-17.

45.

EGFR mutations and HER2/3 protein expression and clinical outcome in Chinese advanced non-small cell lung cancer patients treated with gefitinib.

Xu JM, Han Y, Duan HQ, Gao EM, Zhang Y, Liu XQ, Zhang JS, Toschi L, Galetta D, Azzariti A, Paradiso A.

J Cancer Res Clin Oncol. 2009 Jun;135(6):771-82. doi: 10.1007/s00432-008-0512-1. Epub 2008 Nov 20.

PMID:
19020901
46.

MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients.

Cappuzzo F, Jänne PA, Skokan M, Finocchiaro G, Rossi E, Ligorio C, Zucali PA, Terracciano L, Toschi L, Roncalli M, Destro A, Incarbone M, Alloisio M, Santoro A, Varella-Garcia M.

Ann Oncol. 2009 Feb;20(2):298-304. doi: 10.1093/annonc/mdn635. Epub 2008 Oct 3.

47.

Single-agent and combination therapeutic strategies to inhibit hepatocyte growth factor/MET signaling in cancer.

Toschi L, Jänne PA.

Clin Cancer Res. 2008 Oct 1;14(19):5941-6. doi: 10.1158/1078-0432.CCR-08-0071. Review.

48.

Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients.

Cappuzzo F, Varella-Garcia M, Finocchiaro G, Skokan M, Gajapathy S, Carnaghi C, Rimassa L, Rossi E, Ligorio C, Di Tommaso L, Holmes AJ, Toschi L, Tallini G, Destro A, Roncalli M, Santoro A, Jänne PA.

Br J Cancer. 2008 Jul 8;99(1):83-9. doi: 10.1038/sj.bjc.6604439. Epub 2008 Jun 24.

49.

Epidermal growth factor receptor (EGFR) targeted therapies in non-small cell lung cancer (NSCLC).

Metro G, Finocchiaro G, Toschi L, Bartolini S, Magrini E, Cancellieri A, Trisolini R, Castaldini L, Tallini G, Crino L, Cappuzzo F.

Rev Recent Clin Trials. 2006 Jan;1(1):1-13. Review.

PMID:
18393776
50.

EGFR tyrosine kinase inhibitors: a therapy for a few, for the majority or for all non-small cell lung cancer patients?

Finocchiaro G, Toschi L, Garassino I, De Vincenzo F, Campagnoli E, Zucali P, Cavina R, Ceresoli GL, Santoro A, Cappuzzo F.

Expert Opin Med Diagn. 2007 Oct;1(2):183-91. doi: 10.1517/17530059.1.2.183.

PMID:
23489305

Supplemental Content

Loading ...
Support Center